CSL Share Price

Open 127.86 Change Price %
High 129.29 1 Day 1.61 1.27
Low 127.23 1 Week 2.35 1.86
Close 128.61 1 Month 0.25 0.19
Volume 1360173 1 Year 20.91 19.42
52 Week High 145.00
52 Week Low 91.62
CSL Important Levels
Resistance 2 130.52
Resistance 1 129.73
Pivot 128.38
Support 1 127.49
Support 2 126.70
ASX Australia Most Active Stocks
LYC 0.15 7.14%
TLS 3.90 0.78%
TLS 3.90 0.78%
TLS 3.90 0.78%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
AGO 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
VKA 0.02 100.00%
CAV 0.02 100.00%
CAV 0.02 100.00%
GMD 0.02 100.00%
GMD 0.02 100.00%
RDS 0.02 100.00%
RDS 0.02 100.00%
RDS 0.02 100.00%
AZZ 0.50 78.57%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
AZS 0.01 -50.00%
AZS 0.01 -50.00%
AIR 0.02 -33.33%
AIR 0.02 -33.33%
More..

CSL Ltd (ASX: CSL)

CSL Technical Analysis 2
As on 18th Aug 2017 CSL Share Price closed @ 128.61 and we RECOMMEND Buy for LONG-TERM with Stoploss of 117.70 & Strong Sell for SHORT-TERM with Stoploss of 132.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
CSL Target for August
1st Target up-side 133.05
2nd Target up-side 138
3rd Target up-side 142.94
1st Target down-side 118.95
2nd Target down-side 114
3rd Target down-side 109.06
CSL Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.csl.com.au
CSL Address
CSL
45 Poplar Road
Parkville, VIC 3052
Australia
Phone: 61 3 9389 1911
Fax: 61 3 9389 1434
CSL Latest News
Interactive Technical Analysis Chart CSL Ltd ( CSL ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on CSL Ltd
CSL Business Profile
CSL Limited engages in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Switzerland, Germany, and internationally. The company operates through CSL Behring, bioCSL, and CSL Intellectual Property segments. The CSL Behring segment manufactures, markets, and develops plasma therapies, including plasma products and recombinants that are used to treat coagulation disorders, including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders, cardiac surgery, organ transplantation, and burn treatment, as well as to prevent hemolytic diseases in the newborn. The bioCSL segment manufactures and distributes non-plasma biotherapeutic products, including biological products for human use; vaccines to prevent viral and bacterial diseases; prescription pharmaceuticals to treat a range of human medical conditions; in vitro diagnostic products; and antivenoms to treat victims of venomous snake and spider bites. The CSL Intellectual Property segment engages in the commercialization of intellectual property. In addition, the company markets various vaccines and antivenoms, as well as a range of pharmaceutical products supplied by other manufacturers. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.